Stock Scorer

Royalty Pharma plc (RPRX)

Royalty Pharma plc reported revenue of 674.1M USD for the quarter ending 30 June 2026, up 16.5% from 578.7M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 674.1M +16.5%
Operating Income Q2 '26 · ending 30 June 2026 133.1M -36.5%
Net Income Q2 '26 · ending 30 June 2026 17.9M -44.4%
Operating Cash Flow Q2 '26 · ending 30 June 2026 728.5M +100.1%
Shares Outstanding Q2 '26 · ending 30 June 2026 556.9M -3.7%
EPS Q2 '26 · ending 30 June 2026 1.88 -18.3%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 2.4B1.6B770.9M—
20242024-12-31 2.3B1.3B859M—
20232023-12-31 2.4B1.5B1.1B—
20222022-12-31 2.2B307.1M42.8M—
20212021-12-31 2.3B1.4B619.7M—
20202020-12-31 2.1B1.6B975M—
20192019-12-31 1.8B2.6B2.3B—
20182018-12-31 1.8B1.4B1.4B—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30674.1M
Q1 '262026-03-31630.6M
Q4 '252025-12-31622M
Q3 '252025-09-30609.3M
Q2 '252025-06-30578.7M
Q1 '252025-03-31568.2M
Q4 '242024-12-31593.6M
Q3 '242024-09-30564.7M
Q2 '242024-06-30537.3M
Q1 '242024-03-31568M
Q4 '232023-12-31596.1M
Q3 '232023-09-30536.3M
Q2 '232023-06-30538.2M
Q1 '232023-03-31684M
Q4 '222022-12-31565.7M
Q3 '222022-09-30573.5M
Q2 '222022-06-30536M
Q1 '222022-03-31562M
Q4 '212021-12-31575.7M
Q3 '212021-09-30585.8M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30133.1M
Q1 '262026-03-31563M
Q4 '252025-12-31388.4M
Q3 '252025-09-30427.2M
Q2 '252025-06-30209.8M
Q1 '252025-03-31534.2M
Q4 '242024-12-31361.5M
Q3 '242024-09-30735.1M
Q2 '242024-06-30269.6M
Q1 '242024-03-31-73.8M
Q4 '232023-12-31612.9M
Q3 '232023-09-30151.4M
Q2 '232023-06-30248.8M
Q1 '232023-03-31479M
Q3 '222022-09-30192.2M
Q2 '222022-06-30377.8M
Q1 '222022-03-31219.7M
Q4 '212021-12-31153.4M
Q3 '212021-09-30303.1M
Q2 '212021-06-30744.9M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-3017.9M
Q1 '262026-03-31294.7M
Q4 '252025-12-31214.2M
Q3 '252025-09-30288.2M
Q2 '252025-06-3032.2M
Q1 '252025-03-31239.3M
Q4 '242024-12-31208.2M
Q3 '242024-09-30544M
Q2 '242024-06-30102M
Q1 '242024-03-314.8M
Q4 '232023-12-31494.3M
Q3 '232023-09-3072.1M
Q2 '232023-06-30227.6M
Q1 '232023-03-31340.8M
Q3 '222022-09-30142.7M
Q2 '222022-06-30304.5M
Q1 '222022-03-3151.8M
Q4 '212021-12-317.9M
Q3 '212021-09-30101.9M
Q2 '212021-06-30440.8M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30728.5M
Q1 '262026-03-31718.2M
Q4 '252025-12-31827.1M
Q3 '252025-09-30702.6M
Q2 '252025-06-30364M
Q1 '252025-03-31596.1M
Q4 '242024-12-31742.5M
Q3 '242024-09-30703.6M
Q2 '242024-06-30658.2M
Q1 '242024-03-31664.6M
Q4 '232023-12-31772.6M
Q3 '232023-09-30573.5M
Q2 '232023-06-30607.8M
Q1 '232023-03-311B
Q4 '222022-12-31569.9M
Q3 '222022-09-30538.8M
Q2 '222022-06-30575M
Q1 '222022-03-31460.3M
Q4 '212021-12-31490M
Q3 '212021-09-30469.8M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30556.9M
Q1 '262026-03-31556.8M
Q3 '252025-09-30559.6M
Q2 '252025-06-30562.3M
Q1 '252025-03-31578.1M
Q3 '242024-09-30592.7M
Q2 '242024-06-30596.9M
Q1 '242024-03-31597.5M
Q3 '232023-09-30601.1M
Q2 '232023-06-30605.9M
Q1 '232023-03-31607.3M
Q3 '222022-09-30607.2M
Q2 '222022-06-30607.2M
Q1 '222022-03-31607.2M
Q3 '212021-09-30607.2M
Q2 '212021-06-30607.2M
Q1 '212021-03-31607.1M
Q3 '202020-09-30370M
Q2 '202020-06-30354M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-301.88
Q1 '262026-03-311.91
Q4 '252025-12-311.79
Q3 '252025-09-301.76
Q2 '252025-06-302.30
Q1 '252025-03-312.46
Q4 '242024-12-311.92
Q3 '242024-09-302.55
Q2 '242024-06-301.50
Q1 '242024-03-311.77
Q4 '232023-12-312.52
Q3 '222022-09-301.14
Q2 '222022-06-301.06
Q1 '222022-03-311.44
Q4 '212021-12-311.50
Q3 '212021-09-301.94
Q2 '212021-06-302.49